
|Videos|January 18, 2023
Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement












